^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    COMPANY:
    Oncgnostics

    i
    Other names: Oncgnostics GmbH
    Related tests:
    Evidence

    News

    7ms
    German oncgnostics GmbH‘s innovation in the area of cervical cancer diagnostics now also available in China (Oncgnostics Press Release)
    "The cervical cancer screening test GynTect is now available to physicians and patients in China, the world’s most populous country. The product is the first approved methylation test for triage of HPV-positive cases in China...The molecular biological test GynTect developed by oncgnostics clarifies early on whether a patient with an abnormal finding after undergoing cervical cancer screening has a predisposition for or already has cervical carcinoma (cervical cancer), resulting in the need for prompt treatment."
    Non-US regulatory
    |
    GynTect®